Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.53 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 2/20 | 0.48 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.46 |
| ▸ | GNA15 | P30679 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27638043 | 0.95 | SGMS2 (0.52) | FFAR1KIFC1SGMS2 | |
| SCHEMBL27638080 | 0.88 | FFAR1 (0.50) | FFAR1SGMS2 | |
| SCHEMBL5927406 | 0.87 | LRRK2 (0.49) | FFAR1KIFC1MMP12GPR34 | |
| SCHEMBL5927212 | 0.84 | FFAR1 (0.56) | FFAR1MMP12CTSAACACB | |
| SCHEMBL3974468 | 0.84 | KIFC1 (0.70) | FFAR1KIFC1GPR34 | |
| SCHEMBL5926998 | 0.83 | LRRK2 (0.49) | KIFC1CTSA | |
| SCHEMBL5926919 | 0.82 | LRRK2 (0.48) | KIFC1 | |
| SCHEMBL3971467 | 0.81 | KIFC1 (0.59) | FFAR1KIFC1GPR34 | |
| SCHEMBL3973755 | 0.81 | KIFC1 (0.59) | FFAR1KIFC1GPR34 | |
| SCHEMBL6182302 | 0.79 | SMN1; SMN2 (0.58) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | FFAR1 517/4885KIFC1 4686/4885MMP12 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.